CasLoc logo
All Cases PTAB Litigations UPC Oppositions

AbbVie Inc. v. Hetero Labs Limited

1:14-cv-01137

Overview

Case Number 1:14-cv-01137
Filing Date 2014-09-05
Status Terminated
Termination Date 2014-11-18
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Hetero USA Inc. Operating Company

Represented By

1 Attorneys Listed

Dominick T. Gattuso

Heyman Enerio Gattuso & Hirzel LLP

Tel: +1 (302) 472-7311
Fax: +1 (302) 472-7301

300 Delaware Avenue, Suite 200, Wilmington, DE 19801

Hetero Labs Limited NPE (University / Research)

Represented By

1 Attorneys Listed

Dominick T. Gattuso

Heyman Enerio Gattuso & Hirzel LLP

Tel: +1 (302) 472-7311
Fax: +1 (302) 472-7301

300 Delaware Avenue, Suite 200, Wilmington, DE 19801

Plaintiff

AbbVie Inc. Operating Company

Represented By

6 Attorneys Listed

Robert C. Stanley

Email: robert.stanley@finnegan.com

Mindy L. Ehrenfried

Email: mindy.ehrenfried@finnegan.com

Jonathan R. Davies

Email: jdavies@cooley.com

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Corinne Miller LaGosh

UNDELIVERABLE EMAIL 10/7/15

Mary B. Graham

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 6 proceedings
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (6 found):
U.S. Courts: 6
U.S. District Court 2017-01-13
1:17-cv-00047

AbbVie Inc. v. Aurobindo Pharma Limited

Asserted Patent
Status: DED
U.S. District Court 2015-10-02
1:15-cv-00889

AbbVie Inc. v. Hetero USA Inc.

Asserted Patent
Status: DED
U.S. District Court 2014-09-25
1:14-cv-01236

AbbVie Inc. v. Mylan Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2014-07-18
1:14-cv-00959

AbbVie Inc. v. Aurobindo Pharma Limited

Asserted Patent
Status: DED
U.S. District Court 2013-06-14
1:13-cv-01072

AbbVie Inc. v. Mylan Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-05-15
1:13-cv-00852

AbbVie Inc. v. Hetero USA Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8691878
Solid pharmaceutical dosage form
Filed: 2012-11-12
Issued: 2014-04-08
Active (6.0 yrs remaining)
Expires: 2032-11-12

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th Year Maintenance Fee Paid (8th Year Window Upcoming).

Docket Entries

(21 total)
Pleading / Complaint

COMPLAINT filed against Hetero Labs Limited, Hetero USA Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1582867.) - filed by AbbVie Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(aah) (Entered: 09/08/2014)

Entry #1 • 2014-09-05
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (aah) (Entered: 09/08/2014)

Entry #2 • 2014-09-05
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: July 24,2014. Date of Expiration of Patent: SEE ATTACHED FORM.Thirty Month Stay Deadline: 10/2/2015. (aah) (Entered: 09/08/2014)

Entry #3 • 2014-09-05
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,691,878 B2;. (aah) (Entered: 09/08/2014)

Entry #4 • 2014-09-05
1

Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by AbbVie Inc.. (aah) (Entered: 09/08/2014)

Entry #5 • 2014-09-05
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc